Amazon, LinkedIn, Gilead, & More: Here’s Why These Stocks Are Trending Today

Gilead Misses Expectations

Gilead Sciences, Inc. (NASDAQ:GILD) shares are 8% lower after the biotech/big pharma company missed earnings expectations for the first quarter. For the time period between January 1 and March 31, Gilead reported net income per share of $3.03 on sales of $7.8 billion, versus estimates of $3.14 per share and $8.11 billion. Although Gilead’s overall sales grew 2.8% year-over-year, the company’s mega-hit Harvoni saw its revenue decline 15.7% year-over-year to $3.017 billion. Gilead’s full-year guidance includes net product sales between $30 billion and $31 billion, and product gross margin of 88% to 90%. The hedge fund sentiment around Gilead Sciences, Inc. (NASDAQ:GILD) has been stable, with the number of funds tracked by Insider Monkey owning shares of the company falling by just one quarter-over-quarter to 89 at the end of 2015.

Expedia Beats On Top and Bottom Lines

Expedia Inc (NASDAQ:EXPE) reported first-quarter earnings of $0.09 per share on revenue of $1.9 billion, beating estimates by $0.15 per share and $60 million, respectively. Sales advanced by an annual 38.7% as gross bookings increased 32% (when excluding the impact of acquisitions and eLong) and the number of room nights stayed grew by 37%. Year-to-date, the company has repurchased 2.9 million shares of its stock, for a total cost of $312 million. The number of funds from our database long Expedia Inc (NASDAQ:EXPE) rose by 11 sequentially to 73 during the fourth quarter. Shares of Expedia have gained 8% so far today.

Valeant Files Its Annual Report

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is officially in full compliance with its creditors now that the drug company filed its 2015 annual report with the SEC. Valeant delayed filing its annual report for 2015 due to its need to review its previous accounting. Earlier in the month, Valeant determined that its review was complete and on the April 29, Valeant filed its annual report. Although much of the key data in the annual report had been previously disclosed, Valeant said its fourth quarter 2015 GAAP net loss amounted to $1.12 per share, adjusted EPS stood at $1.55, and revenue was $2.8 billion. Bill Ackman’s Pershing Square is a top shareholder of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and may be actively working behind the scene to turn the company around.

Disclosure: none